Category: News & Events

  Paris, March 4 2015 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces that data from its first pivotal Phase III study with…Continue readingMedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting

Paris, France, April 27 2015 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces it will webcast its post-AAN Clinical Trials Plenary Session, on…Continue readingMedDay to webcast results of its pivotal Phase III study of MD1003 in patients with Progressive Multiple Sclerosis

Dr Frédéric Sedel prendra ses fonctions de Directeur scientifique à la fin du mois d’août Paris, France, 26 juillet 2018 – MedDay, société pharmaceutique pionnière dans le traitement des troubles…Continue readingMedDay nomme Christian Chavy, dirigeant reconnu de l’industrie pharmaceutique, au poste de Directeur Général

Paris, January 29 2015 – MedDay, an emerging biotechnology company focused on the treatment of nervous system disorders, today notes the acceptance of a manuscript relating to results from a…Continue readingMedDay Notes Acceptance of Manuscript into Journal of Multiple Sclerosis and Related Disorders

Edmond de Rothschild Investment Partners a mené le financement de série B aux côtés des investisseurs existants Sofinnova Partners et InnoBio. Large Venture a également participé à l’opération. Les fonds…Continue readingMedDay Pharmaceuticals réalise une nouvelle levée de fonds de 34 millions d’euros

– Second placebo controlled study with MD1003 in Multiple Sclerosis patients – Focus on patients with chronic visual loss following optic neuritis (ON) – Progressive ON sub-group analysis results consistent…Continue readingMedDay provides update on MS-ON study of MD-1003

Paris, France, 25 May 2016 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, announces that an oral presentation entitled “High doses of biotin in progressive…Continue readingMedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial

~Acquisition of Profilomic SA health division fuels the growth of MedDay~ Paris, France, 6 March 2017 – MedDay, a biotechnology company focused on the treatment of nervous system disorders, today…Continue readingMedDay Boosts its Research Capabilities with Profilomic Acquisition

MedDay, a biotechnology company focused on the treatment of nervous system disorders, and DSM Nutritional Products, global leader in innovative nutritional solutions for the pharmaceutical, food, feed and cosmetics industries,…Continue readingMedDay and DSM announce a partnership to produce pharmaceutical grade D-Biotin to treat progressive multiple sclerosis

~ Les résultats de l’étude de phase III seront présentés le 24 avril 2015 au congrès annuel de l’AAN dans le cadre d’une séance plénière sur les essais cliniques ~…Continue readingMedDay annonce avoir atteint le critère principal de son étude pivot de phase III sur le MD1003 chez des patients présentant une sclérose en plaques progressive